Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

DEBRA Research

- PMLiVE

DEBRA and Queen Mary partner to advance epidermolysis bullosa drug development

Around 500,000 people worldwide are affected by the group of rare genetic skin conditions

- PMLiVE

Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery

Approximately 500,000 people worldwide are affected by the rare genetic skin disorders

- PMLiVE

Researchers discover previously unidentified genes linked to rare diseases

Up to 80% of rare disease patients remain undiagnosed after genomic sequencing

- PMLiVE

LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

There is currently no cure for the group of rare inherited skin disorders

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

UK national study supports whole genome sequencing in standard cancer care

The trial combined data from the UK’s 100,000 Genomes Project and NHS records

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links